EDITORIAL

HER2 testing

Guidelines for HER2 testing in the UK

E D Hsi, R R Tubbs

Department of Clinical Pathology, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA

Correspondence to:
Correspondence to:
Dr E D Hsi
Department of Clinical Pathology, L-11, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA; hsie@ccf.org

---

The need to update in a new era of immunohistochemistry testing

---

Keywords: immunohistochemistry; HER2

The first 150 words of the full text of this article appear below.

For decades anatomical pathologists have established and managed diagnostic immunohistochemistry (IHC) laboratories to assist in accurate tissue diagnosis. Although test validation, quality control (QC), and quality assurance (QA) procedures have always been a part of routine operations, test results were always viewed in the context of clinical, morphological, and other IHC test results. However, there has been a shift in the use of these tests. Now, targeted treatments are being determined based on the results of a stand alone IHC test. Specifically, eligibility for traztuzamab is determined by IHC testing (in the UK) or by IHC and/or fluorescent in situ hybridisation (FISH) testing in the USA. Because this represents a fundamental change in the use of IHC in the clinical laboratory, additional attention to the performance and interpretation of this IHC test is warranted. In the current issue of the Journal of Clinical Pathology, Ellis and colleagues . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Winter, J. (2008). Morphological and immunophenotypic analysis of basal-like carcinoma of the breast. Bioscience Horizons 1: 19-27 [Abstract] [Full Text]  
• Kong, S-Y, Kang, J H, Kwon, Y, Kang, H-S, Chung, K-W, Kang, S H, Lee, D H, Ro, J, Lee, E S (2006). Serum HER-2 concentration in patients with primary breast cancer. J. Clin. Pathol. 59: 373-736 [Abstract] [Full Text]  
• Xian, Z-H, Zhang, S-H, Cong, W-M, Wu, W-Q, Wu, M-C (2005). Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J. Clin. Pathol. 58: 500-503 [Abstract] [Full Text]